Kidney Cancer Coverage from Every Angle

Thomas Powles, MD, PhD, on Using Nivolumab and Ipilimumab in Renal Cell Carcinoma

Posted: Tuesday, July 2, 2019

Based on the CheckMate 214 trial, what dosing strategies can be used to limit toxicity with nivolumab/ipilimumab in renal cell carcinoma?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.